Peng et al. demonstrated that magnolol could be an advantageous dietary supplement for OSCC patients since it inhibited the growth of cancer cells and decreased the capacity of OSCC-CSCs from SAS, OECM1, and GNM cell lines, to self-renew and spread through the IL-6/Stat3 pathway [85]. This evidence concerns the gene IL6 and cancer.